Policy | June 25, 2026
Experts call for uniform quality standards for blood and blood components
National conference brings together 160+ experts from six states to advance blood quality and safety standards
National conference brings together 160+ experts from six states to advance blood quality and safety standards
34% of pharma firms have already deployed function-specific AI, with drug discovery, clinical trials, and medical writing emerging as key high-impact use cases
Intas Pharmaceuticals has appointed Girish Bhunje as Senior Vice President – API Operations
The amendments notified under the Clinical Establishments Act, 2010 form part of this broader reform initiative aimed at creating a more responsive and facilitative regulatory ecosystem
Approval makes it the first and only therapy in the EU indicated for both acute and chronic hepatitis C, supported by Phase 3 data
With this commissioning, Shilpa Medicare joins a very small group of Indian companies capable of offering end-to-end ADC Drug Substance development and manufacturing
The safety profile of the Lunsumio and Polivy combination was consistent with the known profiles of the individual study medicines
The company said the safety profile remained consistent with earlier studies and was considered manageable
The backing comes as influenza remains a persistent public health burden
The FDA has granted Priority Review, setting a target decision date of 9 October 2026, potentially accelerating access to a new treatment option for a subset of patients with high-risk colon cancer characterized
Subscribe To Our Newsletter & Stay Updated
